Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

C Droitcourt; Henri Adamski; A Polat; E Polard; M Kerjouan; B Arnouat; M Le Garrec; E Oger; A Dupuy; S Jouneau

doi:10.1111/bjd.16016

Journal articles

Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

C Droitcourt ^{1, 2, 3} Henri Adamski ^{1, *} A Polat ¹ E Polard ¹ M Kerjouan ¹ B Arnouat ¹ M Le Garrec ¹ E Oger ^{3, 1} A Dupuy ^{1, 3} S Jouneau ^{1, 4}

* Corresponding author

1 CHU Pontchaillou [Rennes]

2 CIC - Centre d'Investigation Clinique [Rennes]

3 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins

4 Irset - Institut de recherche en santé, environnement et travail

Abstract : The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Human health and pathology / Dermatology

Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01771415
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 26, 2018 - 1:43:16 PM
Last modification on : Thursday, January 14, 2021 - 11:16:08 AM
Long-term archiving on: : Tuesday, September 25, 2018 - 1:46:59 PM

Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

File

Identifiers

Collections

Citation

Export

Metrics

Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

File

Identifiers

Collections

Citation

Export

Share

Metrics